| | Agent | Human trials | Clinical benefit rate (CR, PR, and SD) | Targets: notes |
| | Imatinib | GIST | 85% (5% CR; 45% PR) | KIT. FDA Approved | | Sunitinib | GIST | 65% (7% PR) | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR a/β, KIT.
FDA Approved | | Sorafenib | Angiosarcoma, GIST | 14% | VEGFR-2, VEGFR-3, PDGFR, c-RAS, b-RAF, KIT | | Pazopanib | Palette
STS | PFS = 20 versus 7 weeks () | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, KIT | | Brivanib | STS
ASCO 2011 | 30% overall
3 PR in angiosarcomas | FGF and VEGF
(FGF-positive did better) | | Cediranib | STS
ASCO 2011 | 78% (43%, PR)
Alveolar soft part sarcoma | VEGFR-1, VEGFR-2, and VEGFR-3 | | Tivantinib | STS
ASCO 2011 | 80% (5%, PR)
Clear cell sarcoma, ASPS | c-Met | | Axitinib | STS, angiosarcoma | N/A | VEGFR-1, VEGFR-2, and VEGFR-3 |
|
|
